Further Research on Anti-CD38 mAbs Warranted in Multiple Myeloma
A systematic review of 8 randomized trials showed that anti-CD38 monoclonal antibodies did not improve overall survival in high-risk subgroups.
Previous Post
The Growing Care Impact of Speech and Physical Therapy in Parkinson Disease: Cynthia Fox, PhD, CCC-SLP
Next Post
Struggling With Step 1 NBME Score Improvements?
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago